Efficacy of CHF1535 Via NEXT DPI Versus pMDI and BDP DPI100µg on PeakExpiratoryFlow in Asthmatic Patients
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate that CHF 1535 NEXT DPI® is non-inferior to the
corresponding dose of CHF 1535 pMDI and superior to marketed beclomethasone DPI 100 µg in
terms of average pre-dose morning Peak Expiratory Flow (PEF) in asthmatic adult patients.